Within the UK, standard therapy activities of 1.1 GBq and 3.7 MBq of I-131 are typically given
to low and high risk ablation patients respectively, while 5.5 GBq is administered for repeat …

Background: Nuclear medicine uses radionuclides in medicine for diagnosis, staging,
therapy, and monitoring the response to therapy. The application of radiopharmaceutical …

Although radioiodine for the treatment of differentiated thyroid cancer is most commonly
given as a fixed, empirical activity, it is well recognised that this leads to a wide range of …

Purpose Dosimetry is rarely performed for the treatment of differentiated thyroid cancer
patients with Na [131I] I (radioiodine), and information regarding absorbed doses delivered …

Radioactive iodine is utilized commonly for ablation of remnant thyroid tissue after
thyroidectomy and treatment of persistent disease and metastases in differentiated thyroid …

Traditionally, nuclear medicine has been regarded mainly as a diagnostic specialty in which
the administration of radioactive substances yields information whose importance far …

In high-activity radioiodine therapies for differentiated thyroid cancer, blood dosimetry has
been developed to estimate the maximum tolerable activity (MTA) of 131I that can be safely …

Purpose To formulate radiation precautions for patients with thyroid cancer who are
undergoing thyroid hormone withdrawal–induced hypothyroidism and iodine 131 (131I) …

No publicly available database (to my knowledge) provides information on facilities and
individuals performing some form of dosimetry to help in selection of activity for 131I therapy …

The treatment of advanced differentiated thyroid cancer (DTC) remains challenging. In spite
of our best efforts, about 15% of patients with high-risk DTC have a significantly reduced life …